BB vs CLOV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

BB

45.4
AI Score
VS
BB Wins

CLOV

44.5
AI Score

Investment Advisor Scores

BB

45score
Recommendation
HOLD

CLOV

45score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric BB CLOV Winner
Forward P/E 47.1698 37.7358 CLOV
PEG Ratio 1.4722 0 Tie
Revenue Growth 26.0% 55.6% CLOV
Earnings Growth 150.0% 0.0% BB
Tradestie Score 45.4/100 44.5/100 BB
Profit Margin 13.1% -0.7% BB
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

BB 1M: +2.7% · 3M: +0.8% CLOV 1M: +3.2% · 3M: +9.1%

Current Technical Phase

BB

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope 0.3%) with fading momentum, RSI 50

RSI (14): 49.8 · Price: $8.61

CLOV

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 54

RSI (14): 54.3 · Price: $4.72

Fundamentals Snapshot

Metric BB CLOV
Market Cap — —
Forward P/E 57.3 31.9
Trailing P/E 70.9 —
Revenue (TTM) — —
Revenue Growth 0.3% 0.6%
Gross Margin 0.8% 0.2%
Operating Margin 0.2% 0.0%
EPS 0.13 -0.05
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, BB is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.